Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
RESEARCH TOOLSreports
SUPN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.53 - $40.28
Previous CloseN/A
Volume41.90K
Average Volume (3M)427.67K
Market Cap
$2.19B
Enterprise Value$1.38B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)31.4
Beta0.86
Next Earnings
Feb 25, 2025EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.07
Shares Outstanding55,219,273
10 Day Avg. Volume552,178
30 Day Avg. Volume427,672
Standard Deviation0.10
R-Squared0.22
Alpha0.00287
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.37
Price to Cash Flow (P/CF)10.30
P/FCF Ratio10.30
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.64
Enterprise Value/Ebitda8.57
Forecast
1Y Price Target
$38.80Price Target Upside12.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Product ApprovalThe FDA has approved Onapgo (SC apomorphine pump) to treat OFF episodes in Parkinson's disease.
Product PerformanceQelbree sales have exceeded expectations, indicating solid demand and a positive market reception.
Revenue GuidanceSupernus raised 2024 revenue guidance to $630-650MM, reflecting better than assumed Trokendi/Oxtellar sales.
Bears Say
Clinical Trial ChallengesNo subgroup profiles or specific data trends stood out in the SPN-820 trial, indicating potential challenges in differentiating treatment effects.
Clinical Trial ResultsDisappointing Phase 2b data from SPN-820 in treatment-resistant patients led to a downgrade of the stock rating.
Clinical Trial StatusThe trial for SPN-820 is on 'pause' as the company continues to analyze more data from the study.
---
Ownership Overview
4.33% Insiders
32.13% Mutual Funds
29.24% Other Institutional Investors
1.83% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SUPN FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was $25.53 and its highest was $40.28 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Supernus Pharmaceuticals’s market cap is $2.19B.
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Feb 25, 2025 which is in 4 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on Nov 04, 2024. The company reported $1.168 earnings per share for the quarter, beating the consensus estimate of $0.443 by $0.725.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is 0.52.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 55,219,273 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $1.168 in its last earnings report, beating expectations of $0.443. Following the earnings report the stock price went up 0.115%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Currently, no hedge funds are holding shares in SUPN
---
Supernus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.80 (12.17% Upside)
$38.80 (12.17% Upside)
Blogger Sentiment
Bullish
SUPN Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 4.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 47.1%
Last 30 Days ▲ 47.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.94%
12-Months-Change
Fundamentals
Return on Equity
6.22%
Trailing 12-Months
Asset Growth
4.48%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
---
SUPN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong growth in key products like Qelbree and GOCOVRI, substantial revenue increases, and positive advancements in the CNS pipeline. Despite challenges with declining sales in legacy products due to generic competition, the company demonstrated a strong cash position and raised its financial guidance, indicating a positive outlook.Read More>---
SUPN Stock 12 Month Forecast
Average Price Target
$38.80
▲(12.17% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Jazz Pharmaceuticals
―
Neurocrine
―
Heron Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering SUPN
1 Year
---